Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes
Erratum to: J Gastrointest Oncol 2026;17:21.
In the February 2026 issue (Vol 17, No. 1) of the Journal of Gastrointestinal Oncology, the article titled “Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes” by Sarelin et al. (1) was published with errors in Figure 3 and in the reported survival rates in the text.
In Figure 3, the survival curves and corresponding survival rates were incorrect due to an error in data processing using SPSS. The survival rates of patients in the ablation and transarterial groups were also reported inaccurately in the text. The Kaplan-Meier curve presented in Figure 4 is correct.
The survival rates reported in the Abstract have been corrected. The correct values are provided below.
“Patients who received surgical treatment according to the BCLC strategy (n=76) had superior survival outcomes than those treated surgically outside the strategy (n=17), with 1-, 3-, and 5-year survival rates of 91.4%, 80.5%, and 69.7%, compared to 82.4%, 38.6%, and 9.7%, respectively (P<0.001).”
The survival rates reported in the Results section under “Long-term outcomes” have been corrected. The correct values are provided below.
“For the 76 surgical patients treated according to the strategy, the 1-, 3-, and 5-year survival rates were 91.4%, 80.5%, and 69.7%, respectively (Figure 3). In contrast, for the 17 patients who received surgical treatment outside the strategy, the 1-, 3-, and 5-year survival rates were 82.4%, 38.6%, and 9.7%, respectively (Figure 3).”
“For the 17 patients who received ablation according to the BCLC strategy, the survival rates were 88.2%, 36.8% and 14.7%, respectively (Figure 4). When ablation treatment was given outside the BCLC, the 1-, 3- and 5-year survival rates were 75.0%, 43.8% and 29.2%, respectively (Figure 4).”
“When the BCLC strategy was followed, the 1-, 3- and 5-year survival rates were 79.0%, 38.6% and 18.5%, respectively (Figure 4). When the transarterial procedure was performed outside the BCLC strategy, the survival rates were 56.6%, 35.6% and 14.2%, respectively (Figure 4).”
The survival rates reported in the Discussion section have been corrected. The correct values are provided below.
“In our study, the 5-year OS rate was 56.6% for all resected patients, consistent with previously published survival rates (14-20).”
“Moreover, these patients showed a dismal 5-year OS rate of 9.7% compared to 69.7% when resection was performed in accordance with the BCLC strategy.”
“In our study, patients treated with ablation had a 1-year survival rate of 82.5%, consistent with previous literature (15-17). However, long-term outcomes were poor, with a 5-year OS rate of only 18.6% and a median survival of 2.4 years.”
“While patients resected beyond the BCLC strategy in our cohort showed poor outcomes, with a 5-year survival rate of 9.7% and a median survival of 2.1 years, the small sample size of only 17 patients limits the reliability of these findings.”
The corrected Figure 3 is provided below.
The authors sincerely apologize for these errors and for any inconvenience caused to the readers and the journal. They confirm that these corrections do not affect the scientific conclusions of the article.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Sarelin N, Kairaluoma V, Nortunen M, et al. Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes. J Gastrointest Oncol 2026;17:21. [Crossref] [PubMed]
